Renal Adjuvant MultiPle Arm Randomised Trial

NCT03288532 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1750

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

University College, London

Collaborators

[object Object]
[object Object]
[object Object]